Multimodal Contrast Agent for Combined Computed Tomography and Magnetic Resonance Imaging Applications

Zheng, Jinzi; Perkins, G.; Kirilova, A.; Allen, Christine; Jaffray, David A.

doi:10.1097/01.rli.0000186568.50265.64

Cited by 83 publications

(61 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, commercially available gadolinium-containing MR agents have been used for CT imaging, but limitations associated with the dosage and costs have prevented their widespread use (123,124). Liposomebased multimodal contrast agents for CT and MRI with prolonged contrast enhancement in vivo have been proposed for cardiovascular imaging as well as image registration and guidance applications in radiation therapy (146). These agents do not confer any obvious benefit on ultrasound imaging.…”

Section: Contrast Agents For Multimodality Imagingmentioning

confidence: 99%

In Vivo mouse imaging and spectroscopy in drug discovery

et al. 2007

View full text Add to dashboard Cite

Imaging modalities such as micro-computed tomography (micro-CT), micro-positron emission tomography (micro-PET), high-resolution MRI, optical imaging, and high-resolution ultrasound have become invaluable tools in preclinical pharmaceutical research. They can be used to non-invasively investigate, in vivo, rodent biology and metabolism, disease models, and pharmacokinetics and pharmacodynamics of drugs. The advantages and limitations of each approach usually determine its application, and therefore a small-rodent imaging laboratory in a pharmaceutical environment should ideally provide access to several techniques. In this paper we aim to illustrate how these techniques may be used to obtain meaningful information for the phenotyping of transgenic mice and for the analysis of compounds in murine models of disease.

show abstract

Section: Contrast Agents For Multimodality Imagingmentioning

confidence: 99%

In Vivo mouse imaging and spectroscopy in drug discovery

et al. 2007

View full text Add to dashboard Cite

show abstract

“…182 Interestingly, multimodal liposomeencapsulated contrast constructs containing both iodine and gadolinium have been developed for combined computed tomography and magnetic resonance imaging applications even up to 3 days after contrast administration. 9,183 In terms of physical modifications, K-edge subtraction and x-ray fluo- rescence imaging have been proposed for improved soft tissue contrast. 30 A higher x-ray dose, i.e., increased photons fluence, may be used to further increase spatial resolution at the expense, however, of a geometrical increase of delivered dose.…”

Section: Ct Contrast Agentsmentioning

confidence: 99%

In vivo small animal imaging: Current status and future prospects

et al. 2010

View full text Add to dashboard Cite

The use of small animal models in basic and preclinical sciences constitutes an integral part of testing new pharmaceutical agents prior to commercial translation to clinical practice. Whole-body small animal imaging is a particularly elegant and cost-effective experimental platform for the timely validation and commercialization of novel agents from the bench to the bedside. Biomedical imaging is now listed along with genomics, proteomics, and metabolomics as an integral part of biological and medical sciences. Miniaturized versions of clinical diagnostic modalities, including but not limited to microcomputed tomography, micromagnetic resonance tomography, microsinglephoton-emission tomography, micropositron-emission tomography, optical imaging, digital angiography, and ultrasound, have all greatly improved our investigative abilities to longitudinally study various experimental models of human disease in mice and rodents. After an exhaustive literature search, the authors present a concise and critical review of in vivo small animal imaging, focusing on currently available modalities as well as emerging imaging technologies on one side and molecularly targeted contrast agents on the other. Aforementioned scientific topics are analyzed in the context of cancer angiogenesis and innovative antiangiogenic strategies under-the-way to the clinic. Proposed hybrid approaches for diagnosis and targeted site-specific therapy are highlighted to offer an intriguing glimpse of the future.

show abstract

“…[2][3][4][5][6][7] They have also been used as contrast agents in computed tomography (CT) and magnetic resonance (MR) imaging, [8][9][10] and as a delivery mechanism of contrast molecules to tumor regions. 11 Some members of this group have previously developed and evaluated a long circulating liposomal-based, nanoparticle contrast agent for blood pool imaging.…”

Section: Introductionmentioning

confidence: 99%

Micro-CT imaging of breast tumors in rodents using a liposomal, nanoparticle contrast agent

Samei¹

2009

IJN

View full text Add to dashboard Cite

A long circulating liposomal, nanoscale blood pool agent encapsulating traditional iodinated contrast agent (65 mg I/mL) was used for micro-computed tomography (CT) imaging of rats implanted with R3230AC mammary carcinoma. Three-dimensional vascular architecture of tumors was imaged at 100-micron isotropic resolution. The image data showed good qualitative correlation with pathologic findings. The approach holds promise for studying tumor angiogenesis and for evaluating anti-angiogenesis therapies.

show abstract

Multimodal Contrast Agent for Combined Computed Tomography and Magnetic Resonance Imaging Applications

Cited by 83 publications

References 66 publications

In Vivo mouse imaging and spectroscopy in drug discovery

In Vivo mouse imaging and spectroscopy in drug discovery

In vivo small animal imaging: Current status and future prospects

Micro-CT imaging of breast tumors in rodents using a liposomal, nanoparticle contrast agent

Contact Info

Product

Resources

About